2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-6-(1,2,4-triazol-1-yl)-1H-benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-6-(1,2,4-triazol-1-yl)-1H-benzimidazole
• 化学式: C₂₀H₁₉N₅O₂
• 分子量: 361.4
• InChiKey: NIHMOVNVZJBDRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• MUCIN PRODUCTION INHIBITOR
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1676575A2

  公开（公告）日：2006-07-05

  To provide a drug useful for prevention or treatment of respiratory diseases accompanying hyper-secretion of mucus, the drug normalizing physiological functions of the respiratory tract by preventing over-production of mucin from the respiratory tract epithelium. A mucin production inhibitor comprising, as an active ingredient, a benzimidazole derivative represented by formula (1) : (wherein A represents a triazole group; R1 and R2 may be identical to or different from each other, and each represents an aliphatic hydrocarbon group which may have an alicyclic hydrocarbon group, or an alicyclic hydrocarbon group; R3 represents a hydrogen atom or a substituent; and R4 represents a hydrogen atom or a protective group for the nitrogen atom) or a pharmacologically acceptable salt thereof.

  提供一种用于预防或治疗伴有粘液分泌过多的呼吸道疾病的药物，该药物通过防止呼吸道上皮过度分泌粘蛋白，使呼吸道的生理功能恢复正常。一种粘蛋白生成抑制剂，其有效成分包括由式（1）代表的苯并咪唑衍生物： (其中 A 代表三唑基团；R1 和 R2 可以彼此相同或不同，并且各自代表可能具有脂环烃基团的脂族烃基团或脂环烃基团；R3 代表氢原子或取代基；R4 代表氢原子或氮原子的保护基团)或其药理学上可接受的盐。
• Mucin production inhibitor
  申请人：Sasaki Eiji

  公开号：US20050222234A1

  公开（公告）日：2005-10-06

  To provide a drug useful for prevention or treatment of respiratory diseases accompanying hyper-secretion of mucus, the drug normalizing physiological functions of the respiratory tract by preventing over-production of mucin from the respiratory tract epithelium. A mucin production inhibitor comprising, as an active ingredient, a benzimidazole derivative represented by formula (1): (wherein A represents a triazole group; R 1 and R 2 may be identical to or different from each other, and each represents an aliphatic hydrocarbon group which may have an alicyclic hydrocarbon group, or an alicyclic hydrocarbon group; R 3 represents a hydrogen atom or a substituent; and R 4 represents a hydrogen atom or a protective group for the nitrogen atom) or a pharmacologically acceptable salt thereof.
• TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR
  申请人：Progenity, Inc.

  公开号：US20200323772A1

  公开（公告）日：2020-10-15

  This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.
• TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR
  申请人：Progenity, Inc.

  公开号：US20210031012A1

  公开（公告）日：2021-02-04

  This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.
• [EN] TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR<br/>[FR] TRAITEMENT DE MALADIE INFLAMMATOIRE FAISANT APPEL À UN DISPOSITIF INGÉRABLE POUR LIBÉRER UN IMMUNOMODULATEUR
  申请人：PROGENITY INC

  公开号：WO2019036382A1

  公开（公告）日：2019-02-21

  This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.